MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Turn Therapeutics

News headline image
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
From Turn Therapeutics
Via GlobeNewswire
Tickers TTRX
News headline image
Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
From Turn Therapeutics
Via GlobeNewswire
Tickers TTRX
News headline image
Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine
From Turn Therapeutics
Via GlobeNewswire
Tickers TTRX
News headline image
Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.
From Turn Therapeutics
Via GlobeNewswire
Tickers TTRX
News headline image
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications
From Turn Therapeutics
Via GlobeNewswire
Tickers TTRX
News headline image
Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline
From Turn Therapeutics
Via GlobeNewswire
Tickers TTRX
News headline image
Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones
From Turn Therapeutics
Via GlobeNewswire
Tickers TTRX
News headline image
Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025
From Turn Therapeutics
Via GlobeNewswire
Tickers TTRX
News headline image
Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors
From Turn Therapeutics
Via GlobeNewswire
Tickers TTRX
News headline image
Turn Therapeutics Appoints Arthur Golden to Board of Directors
From Turn Therapeutics
Via GlobeNewswire
Tickers TTRX
News headline image
Turn Therapeutics to Commence Trading Today on Nasdaq
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Announces Expected First Day of Trading on NASDAQ Global Market
From Turn Therapeutics
Via Business Wire
News headline image
Turn Therapeutics to Host Open Investor Session in Connection with Expected Public Listing on Nasdaq
From Turn Therapeutics
Via Business Wire
News headline image
Turn Therapeutics Intranasal Vaccine Candidate Demonstrates Extended Stability
From Turn Therapeutics
Via Business Wire
News headline image
Turn Therapeutics Begins Clinical Trial of First Topical IL-36/IL-31 Inhibitor for Eczema
From Turn Therapeutics
Via Business Wire
News headline image
Turn Therapeutics Announces Vaccine Breakthrough: Validates 100% VSV Recovery from Petrolatum Carrier at 24 and 72 Hours
From Turn Therapeutics
Via Business Wire
News headline image
Turn Therapeutics Launches Final Crowdfund Round Ahead of Eczema Trial Enrollment, Engages Clear Street to Explore Public Markets
From Turn Therapeutics
Via Business Wire
News headline image
Turn Therapeutics Achieves 24-Hour Stability for Live Vaccine in Intranasal Oil Suspension at Room Temperature, Marking Major Milestone Toward Improving Vaccine Access
From Turn Therapeutics
Via Business Wire
News headline image
Turn Therapeutics Secures $75 Million Investment Commitment Tied to Public Listing
From Turn Therapeutics
Via Business Wire
News headline image
Turn Therapeutics Atopic Dermatitis Candidate Reduces Disease Severity by 57% In-Vivo
From Turn Therapeutics
Via Business Wire
News headline image
Turn Therapeutics invites public investment for expansion of flagship wound formula into eczema, toenail fungus
From Turn Therapeutics
Via Business Wire
News headline image
Turn Therapeutics Announces Human Trial Data for COVID-19 Early Intervention Candidate
From Turn Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story